本研究的目的是评估 177Lu-FAP-2286 肽靶向放射性核素治疗 (PTRT) 治疗晚期肺癌的疗效和安全性。这项单中心前瞻性研究纳入了 9 名诊断为晚期肺癌的患者。这些患者符合纳入标准并接受 177Lu-FAP-2286 的 PTRT。使用 RECIST 1.1 和 PERCIST 1.0 标准评估短期疗效。通过总生存期、无进展生存期 (PFS)、总缓解率、EORTC QLQ-C30 v3.0、东部肿瘤合作组和卡诺夫斯基体能状态来评估长期疗效。使用CTCAE v5.0评估毒性反应。基于RECIST 1.1和PERCIST 1.0标准的结果具有可比性，44%的患者表现出部分代谢反应，33.3%的患者表现出稳定的代谢疾病，22.22%的患者表现出进展的代谢疾病。治疗后最高代谢反应达到66.89%，总体反应率可达77.78%。在长期疗效评估中，中位总生存期和PFS分别为10个月和6个月。 PFS 最低（3 个月）的 2 名患者开始 PTRT 的时间相对较晚。 EORTC QLQ-C30 v3.0、东部肿瘤协作组和卡诺夫斯基体能状态评分显示，177Lu-FAP-2286治疗后患者的整体健康状况、症状反应和生活质量得到改善。临床症状最显着的改善是呼吸困难和癌症相关疼痛。随访期间未观察到 III/IV 级毒性事件，治疗后纤维蛋白原显着下降。177Lu-FAP-2286 有潜力成为晚期肺癌患者可行的 PTRT 选择。版权所有 © 2024 Wolters Kluwer Health，公司保留所有权利。

The aim of this study was to evaluate the efficacy and safety of peptide-targeted radionuclide therapy (PTRT) with 177Lu-FAP-2286 in advanced lung cancer.This single-center prospective study included 9 patients diagnosed with advanced lung cancer. These patients met the inclusion criteria and received PTRT with 177Lu-FAP-2286. Short-term efficacy was assessed using RECIST 1.1 and PERCIST 1.0 criteria. Long-term efficacy was evaluated through overall survival, progression-free survival (PFS), overall response rate, EORTC QLQ-C30 v3.0, Eastern Cooperative Oncology Group, and Karnofsky Performance Status. Toxicity response was assessed using CTCAE v5.0.The results based on RECIST 1.1 and PERCIST 1.0 criteria were comparable, with 44% of patients showing a partial metabolic response, 33.3% with stable metabolic disease, and 22.22% with progressive metabolic disease. The highest metabolic response after treatment reached 66.89%, and the overall response rate could reach 77.78%. In the long-term efficacy assessment, the median overall survival and PFS were 10 months and 6 months, respectively. The 2 patients with the lowest PFS (3 months) started PTRT relatively late. EORTC QLQ-C30 v3.0, Eastern Cooperative Oncology Group, and Karnofsky Performance Status scores showed that the overall health status, symptom response, and quality of life of patients improved after 177Lu-FAP-2286 treatment. The most noticeable improvements in clinical symptoms were dyspnea and cancer-related pain. No grade III/IV toxicity events were observed during follow-up period, and fibrinogen decreased significantly after treatment.177Lu-FAP-2286 has the potential to be a viable PTRT option for patients with advanced lung cancer.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.